BRPI0719093B8 - sistema transdérmico terapêutico com micro reservatórios de pares de ions - Google Patents

sistema transdérmico terapêutico com micro reservatórios de pares de ions

Info

Publication number
BRPI0719093B8
BRPI0719093B8 BRPI0719093A BRPI0719093A BRPI0719093B8 BR PI0719093 B8 BRPI0719093 B8 BR PI0719093B8 BR PI0719093 A BRPI0719093 A BR PI0719093A BR PI0719093 A BRPI0719093 A BR PI0719093A BR PI0719093 B8 BRPI0719093 B8 BR PI0719093B8
Authority
BR
Brazil
Prior art keywords
active substance
ion pair
reservoirs
transdermal system
additive
Prior art date
Application number
BRPI0719093A
Other languages
English (en)
Inventor
Horstmann Michael
Hille Thomas
Müller Walter
Original Assignee
Lts Lohmann Therapie Systeme Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lts Lohmann Therapie Systeme Ag filed Critical Lts Lohmann Therapie Systeme Ag
Publication of BRPI0719093A2 publication Critical patent/BRPI0719093A2/pt
Publication of BRPI0719093B1 publication Critical patent/BRPI0719093B1/pt
Publication of BRPI0719093B8 publication Critical patent/BRPI0719093B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

sistema transdérmico terapêutico com micro reservatórios de pares de íons. a presente invenção refere-se a um sistema terapêutico transdérmico que compreende uma camada posterior impermeável à substância ativa, bem como uma camada protetora que pode ser retirada, impermeável à substância ativa e, pelo menos, uma camada matriz que consiste de polisiloxanos e/ou derivados de polisiloxano que contém microreservatórios que, pelo menos, contém um par iônico de uma substância farmacologicamente ativa e um agente aditivo e a substância ativa é nucleofílica e o aditivo é eletrofílico ou a substância ativa é elotrofílica e o aditivo é nucleofílico.
BRPI0719093A 2006-11-21 2007-11-16 sistema transdérmico terapêutico com micro reservatórios de pares de ions BRPI0719093B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE102006054732A DE102006054732B4 (de) 2006-11-21 2006-11-21 Transdermales therapeutisches System mit Ionenpaar-Mikroreservoiren
DE102006054732.2 2006-11-21
PCT/EP2007/009926 WO2008061677A1 (de) 2006-11-21 2007-11-16 Transdermales therapeutisches system mit ionenpaar-mikroreservoiren

Publications (3)

Publication Number Publication Date
BRPI0719093A2 BRPI0719093A2 (pt) 2013-12-03
BRPI0719093B1 BRPI0719093B1 (pt) 2020-03-24
BRPI0719093B8 true BRPI0719093B8 (pt) 2021-05-25

Family

ID=39106260

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0719093A BRPI0719093B8 (pt) 2006-11-21 2007-11-16 sistema transdérmico terapêutico com micro reservatórios de pares de ions

Country Status (15)

Country Link
US (1) US9089527B2 (pt)
EP (1) EP2094250B1 (pt)
JP (2) JP5578851B2 (pt)
KR (2) KR101629516B1 (pt)
CN (1) CN101522178B (pt)
AT (1) ATE465724T1 (pt)
AU (1) AU2007323357A1 (pt)
BR (1) BRPI0719093B8 (pt)
CA (1) CA2669308A1 (pt)
DE (2) DE102006054732B4 (pt)
ES (1) ES2340971T3 (pt)
IL (1) IL198745A0 (pt)
MX (1) MX2009005342A (pt)
RU (1) RU2009123366A (pt)
WO (1) WO2008061677A1 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW201338813A (zh) 2011-12-12 2013-10-01 洛曼治療系統股份有限公司 經皮遞送系統
DE102011090178A1 (de) * 2011-12-30 2013-07-04 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System mit geringer Neigung zur Spontankristallisation
DE102012213321A1 (de) 2012-07-30 2014-01-30 Robert Bosch Gmbh Verfahren und Vorrichtung zum Betreiben eines Fahrzeugs
WO2014195352A1 (en) 2013-06-04 2014-12-11 Lts Lohmann Therapie-Systeme Ag Transdermal delivery system
US9650338B1 (en) 2016-07-29 2017-05-16 VDM Biochemicals, Inc. Opioid antagonist compounds and methods of making and using
US10238600B2 (en) 2017-04-13 2019-03-26 Richard C. Fuisz Package, system and methods for custody and control of drugs, and method and composition for making an oral soluble film, containing at least one active agent
US9901545B1 (en) 2017-04-13 2018-02-27 Richard C. Fuisz Method and composition for making an oral soluble film, containing at least one active agent
ES2900255T3 (es) * 2017-09-04 2022-03-16 Lts Lohmann Therapie Systeme Ag Sistema de administración transdérmica que incluye un emulsionante
CN112206222A (zh) * 2018-11-09 2021-01-12 北京德默高科医药技术有限公司 含有布洛芬结构类似物的多层经皮给药系统
WO2022178279A1 (en) 2021-02-19 2022-08-25 Nova Thin Film Pharmaceuticals Llc Method and system for manufacturing oral soluble films, compositions of oral soluble films, oral soluble films made by thereby, and methods of use thereof

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3729299A1 (de) 1987-09-02 1989-03-23 Beiersdorf Ag Transdermales therapeutisches system
US5474783A (en) * 1988-03-04 1995-12-12 Noven Pharmaceuticals, Inc. Solubility parameter based drug delivery system and method for altering drug saturation concentration
DE3908047A1 (de) * 1989-03-13 1990-09-20 Desitin Arzneimittel Gmbh Hochdisperse pharmazeutische zusammensetzung
DE4446600A1 (de) 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
US6344211B1 (en) * 1994-12-24 2002-02-05 Lts Lohmann Therapie-Systeme Gmbh Transdermal absorption of active substances from subcooled melts
US5807570A (en) * 1995-09-29 1998-09-15 Cygnus, Inc. Transdermal administration of ropinirole and analogs thereof
JPH09169635A (ja) * 1995-12-20 1997-06-30 Sekisui Chem Co Ltd 経皮吸収製剤
JP4346696B2 (ja) * 1996-05-28 2009-10-21 久光製薬株式会社 経皮治療用装置
US5968547A (en) * 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
DE19738643C2 (de) * 1997-09-04 2001-10-04 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit dem Wirkstoff Scopolaminbase und Verfahren zu seiner Herstellung
DE19834005A1 (de) * 1997-09-25 1999-04-01 Lohmann Therapie Syst Lts Säureadditionssalze von Morphin-Alkaloiden und deren Verwendung
DK1017696T3 (da) 1997-09-25 2002-07-08 Lohmann Therapie Syst Lts Syreadditionssalte af morfin-alkaloider og deres anvendelse
DE19814084B4 (de) * 1998-03-30 2005-12-22 Lts Lohmann Therapie-Systeme Ag D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung
JP4271869B2 (ja) * 1999-02-09 2009-06-03 サムヤン コーポレイション 経皮投与用抗嘔吐剤組成物およびこれを含む製剤
DE19918105C1 (de) 1999-04-22 2000-09-21 Lohmann Therapie Syst Lts Transdermales therapeutisches System mit einem stark wirksamen Neuroleptikum
ATE234081T1 (de) * 1999-07-02 2003-03-15 Lohmann Therapie Syst Lts Mikroreservoirsystem auf basis von polysiloxanen und ambiphilen lösemitteln
ATE493121T1 (de) * 1999-07-15 2011-01-15 Hisamitsu Pharmaceutical Co Perkutane resorbierbare zubereitungen
DE10012908B4 (de) 2000-03-16 2005-03-17 Lts Lohmann Therapie-Systeme Ag Stabilisierte übersättigte transdermale therapeutische Matrixsysteme und Verfahren zu ihrer Herstellung
DE10019311A1 (de) * 2000-04-19 2001-10-31 Lohmann Therapie Syst Lts Transdermale therapuetische Systeme zur Applikation von Moxonidin
US6682757B1 (en) * 2000-11-16 2004-01-27 Euro-Celtique, S.A. Titratable dosage transdermal delivery system
DE10141651B4 (de) * 2001-08-24 2007-02-15 Lts Lohmann Therapie-Systeme Ag Transdermales Therapeutisches System (TTS) mit dem Wirkstoff Fentanyl und Verfahren zu seiner Herstellung
US20040126415A1 (en) * 2002-11-21 2004-07-01 Lu Guang Wei Dermal delivery of a water-soluble selective cyclooxygenase-2 inhibitor
DE10261696A1 (de) * 2002-12-30 2004-07-15 Schwarz Pharma Ag Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base
WO2005037157A1 (en) * 2003-10-14 2005-04-28 Dermatrends, Inc. Enhancing transdermal administration of hydrophilic drugs
WO2005115355A1 (ja) * 2004-05-28 2005-12-08 Hisamitsu Pharmaceutical Co., Inc. 貼付製剤
EP1857103B1 (en) * 2005-02-28 2018-10-24 Hisamitsu Pharmaceutical Co., Inc. Transdermally absorbable preparation
DE102005010255A1 (de) 2005-03-07 2006-09-14 Lts Lohmann Therapie-Systeme Ag Faserfreies transdermales therapeutisches System und Verfahren zu seiner Herstellung

Also Published As

Publication number Publication date
JP2010510264A (ja) 2010-04-02
DE102006054732A1 (de) 2008-05-29
IL198745A0 (en) 2010-02-17
AU2007323357A1 (en) 2008-05-29
EP2094250B1 (de) 2010-04-28
BRPI0719093B1 (pt) 2020-03-24
ES2340971T3 (es) 2010-06-11
JP5578851B2 (ja) 2014-08-27
CN101522178B (zh) 2012-10-03
KR20140057398A (ko) 2014-05-12
DE102006054732B4 (de) 2010-12-30
US9089527B2 (en) 2015-07-28
BRPI0719093A2 (pt) 2013-12-03
WO2008061677A1 (de) 2008-05-29
KR101525369B1 (ko) 2015-06-09
EP2094250A1 (de) 2009-09-02
ATE465724T1 (de) 2010-05-15
JP2014132020A (ja) 2014-07-17
KR101629516B1 (ko) 2016-06-10
MX2009005342A (es) 2009-06-01
CN101522178A (zh) 2009-09-02
RU2009123366A (ru) 2010-12-27
CA2669308A1 (en) 2008-05-29
US20100112064A1 (en) 2010-05-06
DE502007003630D1 (de) 2010-06-10
KR20090082412A (ko) 2009-07-30

Similar Documents

Publication Publication Date Title
BRPI0719093B8 (pt) sistema transdérmico terapêutico com micro reservatórios de pares de ions
BRPI1009842B8 (pt) uso de agonista de tlr9 e agonista de tlr2/6 na preparação de uma composição farmacêutica para tratamento, inibição ou atenuação de uma infecção microbiana, bem como composição farmaceuticamente aceitável compreendendo os referidos agonistas
CR20120638A (es) Métodos de terapia combinada para tratar enfermedades proliferativas
BRPI0818673A2 (pt) terapia de combinação de um anticorpo anti-cd20 tipo ii com um agente ativo anti-bcl-2
BR112015026006A8 (pt) composto em combinação com um fármaco imunomodulador imid®, composição farmacêutica que os compreende, uso dos mesmos e kit
BRPI0809164B8 (pt) Composição para administração tópica e composição farmacêutica compreendendo a referida composição
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
MX380318B (es) Nanoparticula que comprende rapamicina y albumina como agente anticancer.
MX2020010412A (es) Inhibidores de tirosina quinasa de bruton.
BR112012022797A2 (pt) composição farmacêutica resistente a álcool, e, método para tratar uma doença com uma formulação de agente ativo resistente a álcool
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
BR112015023922A2 (pt) composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes
BRPI0611717A2 (pt) composto, composiÇço farmacÊutica e uso do composto
BRPI0607809A2 (pt) uso de uma composição compreendendo nanopartìculas, composição e kit
CR8428A (es) Agente endoparasiticidas para la administracion topica
AR096892A1 (es) Una combinación farmacéutica para el tratamiento del melanoma
CL2007003587A1 (es) Compuestos derivados de pirimidinas sustituidas; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para tratar o prevenir la infeccion de la hepatitis c.
BR112015022650A8 (pt) inibidores de quinase induzível por sal macrocíclico.
BR112015022982A2 (pt) inibidores macrocíclicos de rip2 quinase
BR112016029996A2 (pt) utilização cosmética, composição e método cosmético para tratar os odores corporais
BR112012027463A2 (pt) método terapêutico, composição farmacêutica, uso de tri-iodotironina (t3) ou de análogo bioquímico da mesma, tri-iodotironina (t3) ou um análogo bioquímico da mesma, e, kit
ES2723778T3 (es) Terapia dirigida a células madre cancerosas y contra cáncer resistente a fármacos
CL2010001594A1 (es) Uso de nifurtimox para preparar un medicamento útil en el tratamiento de enfermedades causadas por trichomonadida.
GT200600106A (es) Agentes endoparasiticidas
BRPI0506630A (pt) composição de liberação controlada e método para administrar um medicamento aquoso transmucosal de liberação controlada

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 24/03/2020, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/11/2007 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 18A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2854 DE 16-09-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.